• Something wrong with this record ?

Assessment of delta-9-tetrahydrocannabinol (THC) in saliva and blood after oral administration of medical cannabis with respect to its effect on driving abilities

V. Trojan, L. Landa, R. Hrib, J. Jurica, J. Rychlickova, V. Zvonicek, L. Halamkova, J. Halamek, R. Demlova, S. Belaskova, J. Sliva

. 2022 ; 71 (5) : 703-712. [pub] 20220919

Language English Country Czech Republic

Document type Clinical Trial, Journal Article

Persistent link   https://www.medvik.cz/link/bmc22029549

Medical cannabis has recently been legalized in many countries, and it is currently prescribed with increasing frequency, particularly for treatment of chronic pain resistant to conventional therapy. The psychoactive substance delta-9-tetrahydro-cannabinol (THC) contained in cannabis may affect driving abilities. Therefore, the aims of this study (open-label, monocentric, nonrandomized) were to evaluate blood and saliva concentrations of THC after oral administration of medical cannabis and to assess the time needed for THC levels to decline below a value ensuring legal driving. The study involved 20 patients with documented chronic pain using long-term medical cannabis therapy. They were divided into two groups and treated with two different doses of cannabis in the form of gelatin capsules (62.5 mg or 125 mg). In all patients, the amount of THC was assessed in saliva and in blood at pre-defined time intervals before and after administration. THC levels in saliva were detected at zero in all subjects following administration of both doses at all-time intervals after administration. Assessment of THC levels in blood, however, showed positive findings in one subject 9 h after administration of the lower dose and in one patient who had been given a higher dose 7 h after administration. Our finding suggested that for an unaffected ability to drive, at least 9-10 h should elapse from the last cannabis use.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22029549
003      
CZ-PrNML
005      
20230518115059.0
007      
ta
008      
230113s2022 xr f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.934907 $2 doi
035    __
$a (PubMed)36121021
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Trojan, Václav $u Clinical Pharmacology Unit, Centre for Translational Medicine, International Clinical Research Centre, St. Anne's University Hospital, Brno, Czech Republic $7 xx0301854
245    10
$a Assessment of delta-9-tetrahydrocannabinol (THC) in saliva and blood after oral administration of medical cannabis with respect to its effect on driving abilities / $c V. Trojan, L. Landa, R. Hrib, J. Jurica, J. Rychlickova, V. Zvonicek, L. Halamkova, J. Halamek, R. Demlova, S. Belaskova, J. Sliva
520    9_
$a Medical cannabis has recently been legalized in many countries, and it is currently prescribed with increasing frequency, particularly for treatment of chronic pain resistant to conventional therapy. The psychoactive substance delta-9-tetrahydro-cannabinol (THC) contained in cannabis may affect driving abilities. Therefore, the aims of this study (open-label, monocentric, nonrandomized) were to evaluate blood and saliva concentrations of THC after oral administration of medical cannabis and to assess the time needed for THC levels to decline below a value ensuring legal driving. The study involved 20 patients with documented chronic pain using long-term medical cannabis therapy. They were divided into two groups and treated with two different doses of cannabis in the form of gelatin capsules (62.5 mg or 125 mg). In all patients, the amount of THC was assessed in saliva and in blood at pre-defined time intervals before and after administration. THC levels in saliva were detected at zero in all subjects following administration of both doses at all-time intervals after administration. Assessment of THC levels in blood, however, showed positive findings in one subject 9 h after administration of the lower dose and in one patient who had been given a higher dose 7 h after administration. Our finding suggested that for an unaffected ability to drive, at least 9-10 h should elapse from the last cannabis use.
650    _2
$a lidé $7 D006801
650    _2
$a aplikace orální $7 D000284
650    _2
$a agonisté kanabinoidních receptorů $7 D063386
650    12
$a Cannabis $7 D002188
650    12
$a chronická bolest $7 D059350
650    _2
$a tetrahydrokanabinol $7 D013759
650    12
$a marihuana pro léčebné účely $7 D064086
650    _2
$a sliny $7 D012463
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
700    1_
$a Landa, Leoš $7 ola2003204986 $u Clinical Pharmacology Unit, Centre for Translational Medicine, International Clinical Research Centre, St. Anne's University Hospital, Brno, Czech Republic $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Hřib, Radovan $7 xx0077430 $u Clinical Pharmacology Unit, Centre for Translational Medicine, International Clinical Research Centre, St. Anne's University Hospital, Brno, Czech Republic $u Centre for Pain Management, Department of Anesthesiology and Intensive Care, St. Anne's University Hospital, Brno, Czech Republic
700    1_
$a Jurica, Jan $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Rychlíčková, Jitka $7 xx0230558 $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Zvoníček, Václav, $d 1967- $7 xx0034424 $u Department of Anaesthesia and Intensive Care Medicine, Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Halamkova, Lenka $u Institute of Environmental and Human Health, Department of Environmental Toxicology, Texas Tech University, Lubbock, USA
700    1_
$a Halamek, Jan $u Institute for Forensic Science, Department of Environmental Toxicology, Texas Tech University, Lubbock, USA
700    1_
$a Demlová, Regina $7 xx0063726 $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Belaskova, Silvie $u Clinical Pharmacology Unit, Centre for Translational Medicine, International Clinical Research Centre, St. Anne's University Hospital, Brno, Czech Republic $u Department of Mathematics and Statistics, Faculty of Science, Masaryk University, Brno, Czech Republic
700    1_
$a Slíva, Jiří, $d 1978- $7 xx0070802 $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 71, č. 5 (2022), s. 703-712
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36121021 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y p $z 0
990    __
$a 20230113 $b ABA008
991    __
$a 20230518115053 $b ABA008
999    __
$a ok $b bmc $g 1894744 $s 1180874
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 71 $c 5 $d 703-712 $e 20220919 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
LZP    __
$b NLK198 $a Pubmed-20230113

Find record

Citation metrics

Archiving options